Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Oculis Holding AG before investing.

In this article, we go over a few key elements for understanding Oculis Holding AG’s stock price such as:

• Oculis Holding AG’s current stock price and volume
• Why Oculis Holding AG’s stock price changed recently
• Upgrades and downgrades for OCS from analysts
• OCS’s stock price momentum as measured by its relative strength

About Oculis Holding AG (OCS)

Before we jump into Oculis Holding AG’s stock price, history, target price and what caused it to recently , let’s take a look at some background.

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic, neuro-ophthalmic, and neurological diseases in Switzerland and internationally. The company’s lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis. Oculis Holding AG was formerly known as Oculis SA and changed its name to Oculis Holding AG in March 2023. The company was founded in 2017 and is based in Zug, Switzerland.

Want to learn more about Oculis Holding AG’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Oculis Holding AG.

Oculis Holding AG’s Stock Price as of Market Close

As of August 20, 2026, 4:00 PM, CST, Oculis Holding AG’s stock price was $13.140.

Oculis Holding AG is 0% from its previous closing price of $13.140.

During the last market session, Oculis Holding AG’s stock traded between $13.040 and $13.540. Currently, there are approximately 75.83 million shares outstanding for Oculis Holding AG.

Oculis Holding AG’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Oculis Holding AG Stock Price History

Oculis Holding AG’s (OCS) price is currently up 16.18% so far this month.

During the month of August, Oculis Holding AG’s stock price has reached a high of $13.700 and a low of $11.670.

Over the last year, Oculis Holding AG has hit prices as high as $34.475 and as low as $10.520. Year to date, Oculis Holding AG’s stock is down 34.2%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Oculis Holding AG Stock’s Price to ?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of August 20, 2026, there was 1 analyst who downgraded Oculis Holding AG’s stock and 0 analysts who upgraded over the last month.

Additionally, you'll want to evaluate Oculis Holding AG’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Oculis Holding AG’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Oculis Holding AG’s current valuation based on AAII’s Value Grade is a F, which means it is considered to be Ultra Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Oculis Holding AG (OCS) by visiting AAII Stock Evaluator.

Relative Price Strength of Oculis Holding AG

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of August 20, 2026, Oculis Holding AG has a weighted four-quarter relative price strength of -13.50%, which translates to a Momentum Score of 17 and is considered to be Very Weak.

Want to learn more about how Oculis Holding AG is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Oculis Holding AG Stock Price: Bottom Line

As of August 20, 2026, Oculis Holding AG’s stock price is $13.140, which is 0% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Oculis Holding AG stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.